30 results about "Respiratory syncytial virus RS" patented technology

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of RSV infection.

The present disclosure is directed to compositions and methods for raising immune responses against influenza and respiratory synctial virus by administering combination immunogenic composition against both viruses at the same time. The combination compositions contain an RSV component and one, two, three, four, or more influenza components. The combination compositions provide a greater immune response than that obtained by separately administering the RSV and influenza components.

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and / or prevention of RSV infection.

The invention provides a method for preparing a monoclonal antibody to a respiratory syncytial virus. According to the method for preparing the monoclonal antibody to the respiratory syncytial virus provided by the invention, memory B cells are separated from peripheral blood of a patient who is infected with and recovered from the respiratory syncytial virus recently to further determine genes of a heavy chain variable region and a light chain variable region to express the antibody; murine typhia competent cell VNP20009 is utilized to directly transfect a 293T cell and enable expression of the monoclonal antibody to the respiratory syncytial virus in vitro; neutralization capacity and killing competence of the monoclonal antibody to the respiratory syncytial virus is evaluated after appraisal, so as to screen high-efficiency and scale production-available monoclonal antibodies to the respiratory syncytial virus. According to the method for preparing the monoclonal antibody to the respiratory syncytial virus provided by the invention, as the murine typhia competent cell VNP20009 is utilized to directly transfect the 293T cell, compared with the conventional methods, not only time is saved, but also the application a lot of transfection reagent can be avoided. As transfection of exogenous plasmids to an expression system is a key link of in-vitro expression of the monoclonal antibody, the invention provides a strong support to industrialized application of the technology.

The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and / or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.

The invention provides a fully-humanized monoclonal antibody RSVG71 or RSVG78 specifically combined with adhesion protein (G) of RSV (respiratory syncytial virus) and discloses encoded nucleic acid of the fully-humanized monoclonal antibody, a carrier or a host cell containing the fully-humanized monoclonal antibody and a preparation method of the fully-humanized monoclonal antibody. The invention further discloses an application of the RSV-resistant fully-humanized monoclonal antibody RSVG71 or RSVG78 in prevention and treatment of RSV related diseases and in detection of RSV.

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and / or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind the fusion (F) protein of respiratory syncytial virus (RSV). Also provided herein are methods for preventing, treating and diagnosing viral infection and / or treating one or more symptoms of RSV-mediated disease. Also provided herein are methods of producing antibodies that immunospecifically bind RSV F protein.

The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.

The invention discloses an attenuated strain KM516-AS of respiratory syncytial virus. The attenuated strain is preserved in China Center for Type Culture Collection, with a preservation number CCTCCNO:V201344. The attenuated strain is cultured in vitro and then obtained and purified, so as to produce an attenuated vaccine of the respiratory syncytial virus. After animal is immunized by the vaccine, and the animal obtains good immunogenicity, protectiveness and security.

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind the fusion (F) protein of respiratory syncytial virus (RSV). Also provided are methods for preventing, treating and diagnosing viral infections and / or treating one or more symptoms of RSV-mediated disease. Also provided are methods of producing antibodies that immunospecifically bind RSV F protein.

The invention provides an immune detection reagent for detecting respiratory syncytial virus and a corresponding reagent box. The immune detection reagent comprises anti-respiratory syncytial virus monoclonal antibody 1 as peridium antibody, anti-respiratory syncytial virus monoclonal antibody 2 as biotin labeling antibody and avidin-HRP (horseradish peroxidase). The invention also provides a method for detecting the respiratory syncytial virus by applying the immune detection reagent or the reagent box. The method has relatively high sensitivity and specificity and is easy to clinically use.

The invention discloses a compound for treating respiratory syncytial virus infection, a preparation method and application thereof. The compound is a chemical analogue of cyclopamine, which has the property of inhibiting the replication of respiratory syncytial virus, but does not have the property of inhibiting Hedgehog signaling pathway. The preparation method synthesizes the chemical analogs of the cyclopamine through pharmaceutical chemistry, and screens the analogs through two parallel in vitro tests. The compound can be used to treat respiratory virus infection, paramyxovirus infection, respiratory syncytial virus infection, bronchiolitis caused by respiratory syncytial virus, pneumonia caused by respiratory syncytial virus, otitis media caused by respiratory syncytial virus, It does not have the toxic and side effects of causing fetal malformation, overcomes the teratogenic properties of cyclopamine, and fills in the blank of drugs for treating respiratory syncytial virus infection, especially pediatric drugs.

The invention discloses a nucleic acid detection kit for rapidly detecting respiratory syncytial viruses A and B and an application of the nucleic acid detection kit. The kit comprises the following steps: a nucleic acid amplification reaction liquid, enzyme mixed liquor, a reaction liquid of respiratory syncytial virus A / B, positive control and blank control. According to the nucleic acid detection kit disclosed by the invention, the defects that the nucleic acid detection kit for the respiratory syncytial viruses A and B in the prior art is poor in specificity, relatively low in sensitivity and the like are overcome. The nucleic acid detection kit for the respiratory syncytial viruses A and B disclosed by the invention has the advantages of being high in flux, simple and convenient to operate, high in repeatability, fast and objective in detection result, and has a great application prospect in the aspects such as clinical diagnosis of the respiratory syncytial viruses A and B and disease surveillance.

The invention provides a complete humanized monoclonal antibody RSVG78 specifically binding attachment (G) protein of respiratory syncytial virus (RSV), and discloses coded nucleic acid thereof, vector or host cell containing the complete humanized monoclonal antibi RSV78 and a preparation method thereof. The invention further discloses application of complete humanized anti-RSV monoclonal antibody RSVG78 in prevention and treatment of RSV related diseases and application thereof in RSV detection.

Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.